PO.TB09.01 · 肿瘤生物学

揭示神经母细胞瘤异质性背后的转分化机制

Uncovering transdifferentiation mechanisms underlying heterogeneity in neuroblastoma

海报缩略图:揭示神经母细胞瘤异质性背后的转分化机制
编号 7515 展板 17 时间 4/22 09:00–12:00 区域 Section 31 主讲 Michele Tomanelli, No Degree
分会场 Tumor Heterogeneity
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Michele Tomanelli1, Jennifer Hoti2, Ilaria Medici2, Chaimae Sellak2, Tullio Florio3, Aldo Pagano4

1Department of Experimental Medicine, University of Genoa, Genoa, Italy,2University of Genoa, Genoa, Italy,3Department of Internal Medicine, University of Genoa, Genoa, Italy,4IRCCS Ospedale Policlinico San Martino, Genoa, Italy

摘要 Abstract

中文摘要
神经母细胞瘤是新生儿中最常见的颅外肿瘤,起源于神经嵴来源的细胞。我们利用选定的神经母细胞瘤细胞系,构建了经工程改造以表达非编码RNA NDM29的克隆。这一方法使我们能够研究NDM29在肿瘤细胞分化中的功能,并鉴定旨在限制肿瘤侵袭性的潜在新治疗靶点。包括单细胞测序在内的进一步分析揭示了该模型中存在不同的细胞亚群。随后通过FACS分选将这些亚群分离。在该系统中观察到的细胞异质性反映了神经母细胞瘤患者样本中所发现的复杂性。我们模型的克隆本质以及多个亚群的存在提示,所观察到的异质性源自转分化过程。这些亚群的可塑性是本研究的核心焦点。癌细胞发生转分化的能力是癌症研究中的一个关键方面。在我们的模型中,我们鉴定出一个能够响应VEGF信号并有可能调控肿瘤结节内血管生成过程的亚群。理解该模型中所涉及的、导致产生这一亚群及其他亚群的可塑性机制,可能使我们能够开发旨在对抗肿瘤细胞转分化的靶向治疗策略。
查看英文原文 English abstract
Neuroblastoma is the most prevalent extracranial tumor in newborns and originates from neural crest-derived cells. Using selected Neuroblastoma cell lines, we generated clones engineered to express the non-coding RNA NDM29. This approach allowed us to investigate the function of NDM29 in tumor cell differentiation and to identify potential new therapeutic targets aimed at limiting tumor aggressiveness. Additional analyses, including single-cell sequencing, revealed the existence of distinct cellular subpopulations within this model. These subsets were subsequently separated through FACS sorting. The cellular heterogeneity observed in this system mirrors the complexity found in neuroblastoma patient samples. The clonal nature of our model and the presence of multiple subpopulations suggest that the observed heterogeneity arises from transdifferentiation processes. The plasticity of these subpopulations is a central focus of our study. The ability of cancer cells to undergo transdifferentiation is a key aspect in cancer research. In our model, we identified a subpopulation capable of responding to VEGF signaling and potentially able to regulate the angiogenic process within the tumor nodule. Understanding the plasticity mechanisms involved in this model, which lead to the generation of this and other subpopulations, may enable us to develop targeted therapeutic strategies aimed at counteracting tumor cell transdifferentiation.
利益披露 Disclosure
M. Tomanelli, None.. J. Hoti, None.. I. Medici, None.. C. Sellak, None.. T. Florio, None.. A. Pagano, None.

← 返回 AACR 2026 检索